Can irinotecan dose reduction according to ugt1a1 genotype avoid severe toxicities?
Francesca Daniel(Istituto Oncologico Veneto), Antonio Frassoldati(Italian Oncology Group of Clinical Research), M. Fabbri(Alaska Heart and Vascular Institute), I. Toma(Arcispedale Sant'Anna), Eri Banno(Arcispedale Sant'Anna), A. Moretti(University of Ferrara), Lorenzo Belluomini(University of Ferrara), Luca Martella(Arcispedale Sant'Anna), I. Carandina(Arcispedale Sant'Anna), Federica Lancia(University of Ferrara), M. Marzola(Ospedale Sant'Anna)
Cited by 1
Related Papers
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
|Annals of Oncology|2012|339
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
|Nature Medicine|2022|259
Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy
|Cancer Research|2010|244
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240